Your Best Stock

Abbott Laboratories ABT

$101.89
−$1.60 (-1.55%)
Market open · Sep 24, 1:10 pm ET
After hours $103.49 0.00%
Open$103.77
Prev close$103.49
Day range$101.75 – $104.22
Volume1.80M
Market cap$176.31B
P/E (TTM)33.0
Dividend yield2.39%

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$12.59B+13.0% YoY
Operating profit$1.69B-17.5% YoY
Net profit$928.00M-47.8% YoY
Diluted EPS$0.53-47.5% YoY
Free cash flow$1.99B+28.9% YoY
Operating cash flow$2.49B

Revenue, last 8 quarters

$10.6BSep '24$11.0BDec '24$10.4BMar '25$11.1BJun '25$11.4BSep '25$11.5BDec '25$11.2BMar '26$12.6BJun '26

Net profit, last 8 quarters

$1.6BSep '24$9.2BDec '24$1.3BMar '25$1.8BJun '25$1.6BSep '25$1.8BDec '25$1.1BMar '26$928.0MJun '26

Diluted EPS by quarter

0.94Sep '245.27Dec '240.76Mar '251.01Jun '250.94Sep '251.01Dec '250.61Mar '260.53Jun '26

Free cash flow by quarter

$2.1BSep '24$2.1BDec '24$933.0MMar '25$1.5BJun '25$2.3BSep '25$2.6BDec '25$916.0MMar '26$2.0BJun '26

Annual revenue

$34.6BFY20$43.1BFY21$43.7BFY22$40.1BFY23$42.0BFY24$44.3BFY25

Profitability & balance sheet

Gross margin56.6%
Operating margin15.8%
Net margin11.6%
Return on equity10.7%
Return on assets5.6%
Return on invested capital7.8%
Current ratio1.38
Liabilities / assets52.6%
Cash & investments$5.60B
Total debt$32.61B
Net cash (debt)-$27.01B
Free cash flow / sales16.8%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Medical devices$5.85B 46.5%
  • Diagnostic Products$3.09B 24.6%
  • Nutritional Products$2.14B 17.0%
  • Established Pharmaceutical Products$1.50B 11.9%
  • Other$5.00M 0.0%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $12.59B $11.16B $44.33B $11.46B $11.37B
Total Operating Revenue $12.59B $11.16B $44.33B $11.46B $11.37B
Cost of Revenue $5.33B $4.89B $19.32B $4.92B $5.08B
Gross Profit $7.27B $6.27B $25.01B $6.54B $6.29B
Operating Expense $5.58B $4.93B $16.96B $4.29B $4.24B
Selling and Admin Expenses $4.03B $3.74B $12.33B $3.13B $3.05B
Research & Development $892.00M $767.00M $2.94B $735.00M $766.00M
Depreciation & Amortization & Depletion $658.00M $422.00M $1.68B $422.00M $420.00M
-Depreciation & Amortization $658.00M $422.00M $1.68B $422.00M $420.00M
Operating Profit $1.69B $1.35B $8.05B $2.25B $2.06B
Net Non-Operating Interest Income (Expense) -$299.00M -$68.00M -$185.00M -$42.00M -$44.00M
Non-Operating Interest Income $52.00M $106.00M $308.00M $78.00M $77.00M
Non-Operating Interest Expense $351.00M $174.00M $493.00M $120.00M $121.00M
Other Income (Expense) $130.00M $172.00M $598.00M $149.00M $167.00M
Gain on Sale of Security -$4.00M $13.00M $50.00M $15.00M $17.00M
Other Non-Operating Income (Expenses) $134.00M $159.00M $548.00M $134.00M $150.00M
Pretax Profit $1.52B $1.45B $8.47B $2.36B $2.18B
Tax $596.00M $372.00M $1.94B $582.00M $536.00M
Net Profit $928.00M $1.08B $6.52B $1.78B $1.64B
Profit from Continuing Operations $928.00M $1.08B $6.52B $1.78B $1.64B
Net Income to Parent Company $928.00M $1.08B $6.52B $1.78B $1.64B
Net Income to Common Stockholders $928.00M $1.08B $6.52B $1.78B $1.64B
Basic EPS $0.53 $0.62 $3.73 $1.02 $0.94
Diluted EPS $0.53 $0.61 $3.72 $1.01 $0.94
Dividend Per Share $0.63 $0.63 $2.36 $0.59 $0.59

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $109.22B $110.43B $86.71B $86.71B $84.18B
Total Current Assets $24.52B $25.51B $26.00B $26.00B $24.84B
Cash and Cash Equivalents & Short-Term Investments $5.60B $7.30B $8.94B $8.94B $7.73B
-Cash and Cash Equivalents $5.10B $6.80B $8.52B $8.52B $7.51B
-Short Term Investments $499.00M $492.00M $417.00M $417.00M $222.00M
Receivables $11.60B $11.22B $10.57B $10.57B $10.40B
-Accounts Receivable $8.60B $8.21B $7.93B $7.93B $8.14B
-Other Receivables $3.00B $3.01B $2.64B $2.64B $2.26B
Inventory $7.32B $6.99B $6.49B $6.49B $6.71B
Total Non-Current Assets $84.70B $84.92B $60.72B $60.72B $59.34B
Net PPE $12.81B $12.38B $11.82B $11.82B $11.50B
-Gross PPE $26.47B $25.74B $25.22B $25.22B $24.82B
-Accumulated Depreciation -$13.66B -$13.36B -$13.41B -$13.41B -$13.31B
Investments and Advances $1.11B $1.09B $918.00M $918.00M $951.00M
-Available for Sale Securities $747.00M $727.00M $597.00M $597.00M $633.00M
Goodwill and Other Intangible Assets $52.46B $53.10B $29.56B $29.56B $29.57B
-Goodwill $35.24B $35.22B $24.04B $24.04B $23.97B
-Other Intangible Assets $17.21B $17.88B $5.53B $5.53B $5.59B
Other Non-Current Assets $18.32B $18.36B $18.42B $18.42B $17.32B
Total Liabilities $57.45B $57.73B $33.94B $33.94B $32.92B
Total Current Liabilities $17.81B $18.38B $16.50B $16.50B $14.58B
Payables $6.30B $6.38B $6.59B $6.59B $5.62B
-Accounts Payable $4.79B $4.68B $4.24B $4.24B $4.12B
-Total Tax Payable $411.00M $598.00M $569.00M $569.00M $469.00M
-Dividends Payable $1.09B $1.10B $1.10B $1.10B $1.03B
Current Accrued Expenses $8.51B $7.59B $6.88B $6.88B $7.62B
Short-Term Debt and Capital Lease Obligation $3.01B $4.41B $3.03B $3.03B $1.35B
-Current Debt $3.01B $4.41B $3.03B $3.03B $1.35B
Total Non-Current Liabilities $39.64B $39.35B $17.45B $17.45B $18.34B
Long Term Debt and Capital Lease Obligation $29.60B $29.64B $10.83B $10.83B $11.60B
-Long Term Debt $29.60B $29.64B $9.90B $9.90B $11.60B
Other Non-Current Liabilities $10.04B $9.71B $2.54B $2.54B $6.74B
Total Equity $51.76B $52.70B $52.77B $52.77B $51.26B
Stockholders' Equity $51.11B $52.06B $52.13B $52.13B $50.95B
Capital Stock $25.50B $25.35B $25.53B $25.53B $25.41B
-Common Stock $25.50B $25.35B $25.53B $25.53B $25.41B
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Retained Earnings $49.79B $49.96B $49.78B $49.78B $49.10B
Less: Treasury Stock $17.97B $16.94B $17.18B $17.18B $16.88B
Gains/Losses Not Affecting Retained Earnings -$6.21B -$6.31B -$6.00B -$6.00B -$6.68B
Minority Interests $652.00M $640.00M $641.00M $641.00M $310.00M
-Other Payable $682.00M $682.00M
Long Term Accounts Payable and Other Payables $1.40B $1.40B
-Long Term Capital Lease Obligation $931.00M $931.00M
Non-Current Deferred Liabilities $559.00M $559.00M
Employee Benefits $2.13B $2.13B

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow $2.49B $1.32B $9.57B $3.32B $2.79B
Net cash flow from continuing operations $2.49B $1.32B $9.57B $3.32B $2.79B
Net Income from Continuing Operations $928.00M $1.08B $6.52B $1.78B $1.64B
Depreciation & Depletion & Amortization $1.06B $803.00M $3.12B $792.00M $791.00M
Other Non-Cash Items $1.02B -$420.00M $221.00M
Change in Working Capital -$687.00M -$462.00M -$803.00M $110.00M $11.00M
-Change in Receivables -$386.00M -$42.00M -$652.00M $222.00M -$202.00M
-Change in Inventory -$301.00M -$420.00M $195.00M $234.00M $213.00M
Net cash flow from investing -$673.00M -$20.32B -$2.42B -$913.00M -$457.00M
Net Cash Flow from Continuing Investing Activities -$673.00M -$20.32B -$2.42B -$913.00M -$457.00M
Net PPE Purchase and Sale -$497.00M -$399.00M -$2.17B -$689.00M -$496.00M
Net Business Purchase and Sale -$164.00M -$19.80B -$105.00M -$20.00M -$55.00M
Net Investment Purchase and Sale -$26.00M -$161.00M -$164.00M -$210.00M $90.00M
Net Other Investing Changes $14.00M $34.00M $18.00M $6.00M $4.00M
Financing Cash Flow -$3.52B $17.31B -$6.31B -$1.40B -$1.76B
Net Cash Flow from Continuing Financing Activities -$3.52B $17.31B -$6.31B -$1.40B -$1.76B
Net Issuance Payments Of Debt -$1.37B $18.48B -$1.61B -$70.00M -$493.00M
Net Common Stock Issuance -$1.05B -$180.00M -$893.00M -$302.00M -$305.00M
Cash Dividends Paid -$1.10B -$1.10B -$4.12B -$1.03B -$1.03B
Proceeds from Stock Option Exercised $3.00M $116.00M $396.00M $5.00M $69.00M
Ending Cash Balance $5.10B $6.80B $8.52B $8.52B $7.51B
Net Change in Cash -$1.70B -$1.70B $835.00M $1.01B $570.00M
Beginning Cash Balance $6.80B $8.52B $7.62B $7.51B $6.95B
Effect of Exchange Rate Changes $4.00M -$23.00M $71.00M $6.00M -$10.00M
Free Cash Flow $1.99B $916.00M $7.40B $2.63B $2.29B
Gain/Loss from Continuing Operations $65.00M
-Change in Prepaid Assets -$1.30B
-Change in Payables and Accrued Expense $949.00M
Net Other Financing Charges -$82.00M $0.00 $0.00
Scroll to Top